Cardiovascular outcomes in patients with coronary artery disease and elevated lipoprotein(a): implications for the OCEAN(a)-outcomes trial population
European Heart Journal Open · 03.07.2023 · 3 (4)
DOI: 10.1093/ehjopen/oead077 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Heart Journal Open, online erschienen am 27.08.2023. Verfasst von Arthur Shiyovich und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Aims
The ongoing Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction [OCEAN(a)]-Outcomes trial is evaluating whether Lp(a) lowering can reduce the incidence of cardiovascular events among patients with prior myocardial infarction (MI) or percutaneous coronary intervention (PCI) and elevated Lp(a) (≥200 nmol/L). The purpose of this study is to evaluate the association of elevated Lp(a) with cardiovascular outcomes in an observational cohort resembling the OCEAN(a)-Outcomes trial main enrolment criteria. Methods and results This study included patients aged 18–85 years with Lp(a) measured as part of their clinical care between 2000 and 2019. While patients were required to have a history of MI, or PCI, those with severe kidney dysfunction or a malignant neoplasm were excluded. Elevated Lp(a) was defined as ≥200 nmol/L consistent with the OCEAN(a)-Outcomes trial. The primary outcome was a composite of coronary heart disease death, MI, or coronary revascularization. Natural language processing algorithms, billing and ICD codes, and laboratory data were employed to identify outcomes and covariates. A total of 3142 patients met the eligibility criteria, the median age was 61 (IQR: 52–73) years, 28.6% were women, and 12.3% had elevated Lp(a). Over a median follow-up of 12.2 years (IQR: 6.2–14.3), the primary composite outcome occurred more frequently in patients with versus without elevated Lp(a) [46.0 vs. 38.0%, unadjHR = 1.30 (95% CI: 1.09–1.53), P = 0.003]. Following adjustment for measured confounders, elevated Lp(a) remained independently associated with the primary outcome [adjHR = 1.33 (95% CI: 1.12–1.58), P = 0.001].
Conclusion
In an observational cohort resembling the main OCEAN(a)-Outcomes Trial enrolment criteria, patients with an Lp(a) ≥200 nmol/L had a higher risk of cardiovascular outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
- Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
- Cardiology Division, Massachusetts General Hospital, Harvard Medical School, and Baim Institute for Clinical Research, Boston, MA 02115, USA.
- Center for Observational Research, Amgen Inc., Thousand Oaks, CA 91320, USA.
- Department of Cardiovascular Medicine, Division of Cardiovascular Prevention and Wellness, Houston Methodist DeBakey Heart and Vascular Center, Houston, TX 77030, USA.
- Global Development, Amgen Inc., Thousand Oaks, CA 91320, USA.
ORCID-Profile: Arthur Shiyovich, Adam N Berman, Brittany Weber, Khurram Nasir, Deepak L Bhatt
Zitieren
APA
Shiyovich, A., Berman, A. N., Besser, S. A., Biery, D. W., Huck, D. M., Weber, B., Cannon, C., Januzzi, J. L., Booth, J. N., Nasir, K., Di Carli, M. F., López, J. A. G., Kent, S. T., Bhatt, D. L., & Blankstein, R. (2023). Cardiovascular outcomes in patients with coronary artery disease and elevated lipoprotein(a): implications for the OCEAN(a)-outcomes trial population. European Heart Journal Open, 3(4). https://doi.org/10.1093/ehjopen/oead077
Vancouver
Shiyovich A, Berman AN, Besser SA, Biery DW, Huck DM, Weber B, et al. Cardiovascular outcomes in patients with coronary artery disease and elevated lipoprotein(a): implications for the OCEAN(a)-outcomes trial population. European Heart Journal Open. 2023;3(4). doi:10.1093/ehjopen/oead077
BibTeX
@article{Shiyovich2023,
author = {Shiyovich, Arthur and Berman, Adam N and Besser, Stephanie A and Biery, David W and Huck, Daniel M and Weber, Brittany and Cannon, Christopher and Januzzi, James L and Booth, John N and Nasir, Khurram and Di Carli, Marcelo F and López, J Antonio G and Kent, Shia T and Bhatt, Deepak L and Blankstein, Ron},
title = {Cardiovascular outcomes in patients with coronary artery disease and elevated lipoprotein(a): implications for the OCEAN(a)-outcomes trial population},
journal = {European Heart Journal Open},
year = {2023},
volume = {3},
number = {4},
doi = {10.1093/ehjopen/oead077}
}
EUVIMED